Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences Ltd (Nasdaq: TLSA) has announced that CEO Dr. Kunwar Shailubhai will present at the 2022 BIO CEO & Investor Conference on February 14-15 in New York City. The company is pioneering novel immunotherapy delivery methods, focusing on its lead product, foralumab, an entirely human antibody. Recent studies suggest that nasally administered foralumab can effectively immunomodulate in COVID-19 patients and has shown promise for treating multiple sclerosis and inflammatory bowel diseases. Interim results will be shared in Q1 2022.
Tiziana Life Sciences Ltd (Nasdaq: TLSA) announced an amendment to its Investigational New Drug (IND) application for the oral formulation of foralumab, aimed at patients with mild-to-moderately active Crohn’s Disease. This would mark the first oral immunotherapy for this condition. If accepted by the FDA, Tiziana anticipates completing the Phase 1b clinical study by Q4 2022. The trial's primary focus is on safety, with a secondary assessment of pharmacodynamics. The amendment allows for a broader patient population and a shorter dosing regimen, addressing prior challenges in patient enrollment.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) announced its CEO and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B. Riley Securities 2022 Oncology Conference on January 27, 2022, at 4:00 p.m. EDT. The discussion will provide company updates focusing on breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer and innovative drug delivery technologies. Tiziana's leading candidates include intranasal foralumab and milciclib, both showing favorable safety profiles and clinical responses in studies.
Tiziana Life Sciences (Nasdaq: TLSA) has announced a stock repurchase program authorized by its Board of Directors, allowing for the buyback of up to $5 million of the Company's common shares. This program is effective until December 31, 2022, and will utilize the Company's working capital. Executive Chairman Gabriele Cerrone expressed confidence in Tiziana’s growth opportunities, deeming the buyback an attractive use of capital, supported by a strong balance sheet. Tiziana develops innovative therapies through novel drug delivery methods that may enhance efficacy and safety.
Tiziana Life Sciences (Nasdaq: TLSA) announced the passing of Dr. Thomas Adams on January 9, 2022. He had served on the company's Board of Directors since February 2021. CEO Kunwar Shailubhai expressed deep sadness over Dr. Adams' loss, highlighting his value and inspiration to the team. Tiziana is focused on developing transformative therapies through innovative drug delivery methods, such as intranasal and oral routes, which aim to enhance safety and efficacy. The company’s lead candidates include intranasal foralumab and milciclib, showing promising safety profiles in clinical studies.
Tiziana Life Sciences (TLSA) announced a positive update regarding its treatment for secondary progressive multiple sclerosis (SPMS) using intranasal foralumab. The FDA has allowed enrollment of a second patient in the clinical trial, following favorable data from the first patient after three months of treatment, indicating safety and a positive response. Tiziana plans to expand its clinical trials in 2022 to address other conditions such as Crohn's Disease and Type 1 Diabetes. The ongoing monitoring of patient responses is expected to provide further insights by April 2022.
Tiziana Life Sciences (Nasdaq: TLSA) announced participation at the virtual Biotech Showcase Conference on January 10-12 and 17-19, 2022. Senior management will present and be available for one-on-one meetings throughout the event. Tiziana focuses on innovative drug delivery methods, including nasal, oral, and inhalation routes, to enhance immunotherapy efficacy and safety. Their lead candidates include intranasal foralumab and milciclib, both showing promising clinical results. For more details about the conference, registration is available online.
Tiziana Life Sciences plc has restructured its corporate framework by establishing Tiziana Life Sciences Ltd as its new parent company. This change, formalized on October 20, 2021, involved a two-for-one Share Capital Consolidation, allowing shareholders to maintain their ownership proportions. The newly consolidated shares commenced trading on NASDAQ on the same date. Tiziana continues its focus on developing innovative therapeutics for diseases including cancer, inflammation, and infections, notably progressing with its anti-CD3 monoclonal antibody, Foralumab.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced a significant corporate restructuring, establishing Tiziana Life Sciences Ltd as the new parent company, effective October 20, 2021. The scheme of arrangement has been sanctioned by the Court, and the Old Tiziana shares will be delisted on October 21, 2021. Following a two-for-one share capital consolidation, the new shares are set to begin trading on NASDAQ. Tiziana specializes in innovative therapeutics for oncology and autoimmune diseases, with upcoming Phase 2 trials for its lead drug, Foralumab.
Tiziana Life Sciences (TLSA) announced that Gabriele Cerrone, the Executive Chairman, increased his shareholding by purchasing 60,000 ordinary shares at 55p each, elevating his total stake from 34.208% to 34.238%. This acquisition occurred on October 4, 2021, and is in line with the UK Takeover Code's regulations. Tiziana focuses on innovative therapeutic developments for conditions including oncology and autoimmune diseases, with upcoming Phase 2 studies for Foralumab in Crohn's Disease and multiple sclerosis.